136 related articles for article (PubMed ID: 28254951)
21. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
[TBL] [Abstract][Full Text] [Related]
22. Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
Cheng Y; Ma L; Chang SY; Humphreys WG; Li W
Drug Metab Dispos; 2016 Aug; 44(8):1372-80. PubMed ID: 27226352
[TBL] [Abstract][Full Text] [Related]
23. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
[TBL] [Abstract][Full Text] [Related]
24. A pharmacokinetic drug-drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects.
Juif PE; Boehler M; Donazzolo Y; Bruderer S; Dingemanse J
Eur J Clin Pharmacol; 2017 Sep; 73(9):1121-1128. PubMed ID: 28639119
[TBL] [Abstract][Full Text] [Related]
25. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction.
Shou M; Hayashi M; Pan Y; Xu Y; Morrissey K; Xu L; Skiles GL
Drug Metab Dispos; 2008 Nov; 36(11):2355-70. PubMed ID: 18669588
[TBL] [Abstract][Full Text] [Related]
26. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.
Ripp SL; Mills JB; Fahmi OA; Trevena KA; Liras JL; Maurer TS; de Morais SM
Drug Metab Dispos; 2006 Oct; 34(10):1742-8. PubMed ID: 16837568
[TBL] [Abstract][Full Text] [Related]
27. Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
Dutreix C; Munarini F; Lorenzo S; Roesel J; Wang Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1223-34. PubMed ID: 24085261
[TBL] [Abstract][Full Text] [Related]
28. Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines.
Vrzal R; Kubesova K; Pavek P; Dvorak Z
Toxicol Lett; 2010 Mar; 193(2):183-8. PubMed ID: 20080160
[TBL] [Abstract][Full Text] [Related]
29. Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
Rodrigues AD; Wood LS; Vourvahis M; Rowland A
Clin Pharmacol Ther; 2022 Feb; 111(2):425-434. PubMed ID: 34623637
[TBL] [Abstract][Full Text] [Related]
30. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
[TBL] [Abstract][Full Text] [Related]
31. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
Guo J; Zhou D; Li Y; Khanh BH
Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
[TBL] [Abstract][Full Text] [Related]
32. Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
Motta P; Pons N; Pagliarusco S; Pellegatti M; Bonomo F
Drug Metab Dispos; 2011 Mar; 39(3):363-72. PubMed ID: 21149541
[TBL] [Abstract][Full Text] [Related]
33. Study of the ketohexokinase inhibitor PF-06835919 as a clinical cytochrome P450 3A inducer: Integrated use of oral midazolam and liquid biopsy.
Qiu R; Fonseca K; Bergman A; Lin J; Tess D; Newman L; Fahmy A; Useckaite Z; Rowland A; Vourvahis M; Rodrigues D
Clin Transl Sci; 2024 Jan; 17(1):e13644. PubMed ID: 38108609
[TBL] [Abstract][Full Text] [Related]
34. Establishment of In Silico Prediction Models for CYP3A4 and CYP2B6 Induction in Human Hepatocytes by Multiple Regression Analysis Using Azole Compounds.
Nagai M; Konno Y; Satsukawa M; Yamashita S; Yoshinari K
Drug Metab Dispos; 2016 Aug; 44(8):1390-8. PubMed ID: 27208383
[TBL] [Abstract][Full Text] [Related]
35. Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Björkhem-Bergman L; Bäckström T; Nylén H; Rönquist-Nii Y; Bredberg E; Andersson TB; Bertilsson L; Diczfalusy U
Drug Metab Pharmacokinet; 2014; 29(4):352-5. PubMed ID: 24522201
[TBL] [Abstract][Full Text] [Related]
36. Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor.
Sahi J; Milad MA; Zheng X; Rose KA; Wang H; Stilgenbauer L; Gilbert D; Jolley S; Stern RH; LeCluyse EL
J Pharmacol Exp Ther; 2003 Sep; 306(3):1027-34. PubMed ID: 12766253
[TBL] [Abstract][Full Text] [Related]
37. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
Xu L; Chen Y; Pan Y; Skiles GL; Shou M
Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
[TBL] [Abstract][Full Text] [Related]
38. Application of a "Fit for Purpose" PBPK Model to Investigate the CYP3A4 Induction Potential of Enzalutamide.
Narayanan R; Hoffmann M; Kumar G; Surapaneni S
Drug Metab Lett; 2016; 10(3):172-179. PubMed ID: 27604990
[TBL] [Abstract][Full Text] [Related]
39. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies.
Boof ML; Alatrach A; Ufer M; Dingemanse J
Eur J Clin Pharmacol; 2019 Feb; 75(2):195-205. PubMed ID: 30284597
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.
Yeo KP; Lowe SL; Lim MT; Voelker JR; Burkey JL; Wise SD
Br J Clin Pharmacol; 2006 Feb; 61(2):200-10. PubMed ID: 16433874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
